CDSCO Panel Approves AstraZeneca’s Protocol Amendment Proposal to Study Capivasertib Plus Abiraterone
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major AstraZeneca’s proposal for amendment of protocol for the clinical study ” A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients with DeNovo Metastatic […]